Last reviewed · How we verify
CNV1014802
At a glance
| Generic name | CNV1014802 |
|---|---|
| Also known as | BIIB074 |
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- 802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia (PHASE3)
- 802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia (PHASE3)
- Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy (PHASE2)
- Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy (PHASE1)
- Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074 (PHASE2)
- A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia (PHASE2)
- A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen (PHASE1)
- Study to Evaluate the Efficacy and Safety of BIIB074 in Neuropathic Pain From Lumbosacral Radiculopathy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CNV1014802 CI brief — competitive landscape report
- CNV1014802 updates RSS · CI watch RSS
- Biogen portfolio CI